Drug Type Shared antigen vaccine, Therapeutic vaccine, Genetically engineered subunit vaccine |
Synonyms GSK 2302024A, GSK2302024A, WT1-A10+AS15 ASCI |
Target |
Action inhibitors |
Mechanism WT1 inhibitors(Wilms' Tumour 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | Phase 2 | United States | 11 Apr 2011 | |
| HER2 Positive Breast Cancer | Phase 2 | Belgium | 11 Apr 2011 | |
| HER2 Positive Breast Cancer | Phase 2 | France | 11 Apr 2011 | |
| HER2 Positive Breast Cancer | Phase 2 | Germany | 11 Apr 2011 | |
| HER2 Positive Breast Cancer | Phase 2 | Italy | 11 Apr 2011 | |
| HER2 Positive Breast Cancer | Phase 2 | Russia | 11 Apr 2011 | |
| HER2 Positive Breast Cancer | Phase 2 | United Kingdom | 11 Apr 2011 | |
| HER2-negative breast cancer | Phase 2 | United States | 11 Apr 2011 | |
| HER2-negative breast cancer | Phase 2 | Belgium | 11 Apr 2011 | |
| HER2-negative breast cancer | Phase 2 | France | 11 Apr 2011 |
Phase 2 | 66 | Aromatase inhibitor+recombinant WT1 Antigen-Specific Cancer (Cohort A-GSK2302024A Group) | xgvjieddom = cjjssigfty dnhjouwsca (ubmtcvnwpy, egshnugxnn - cmhvznesbb) View more | - | 25 May 2017 | ||
(Cohort A-Placebo Group) | xgvjieddom = ncsagndgkb dnhjouwsca (ubmtcvnwpy, dvsccpqjsv - mevvqlnvdn) View more |





